Jonas Bybjerg-Grauholm
Statens Serum Institut
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jonas Bybjerg-Grauholm.
Nature Genetics | 2017
Daniel J. Weiner; Emilie M. Wigdor; Stephan Ripke; Raymond K. Walters; Jack A. Kosmicki; Jakob Grove; Kaitlin E. Samocha; Jacqueline I. Goldstein; Aysu Okbay; Jonas Bybjerg-Grauholm; Thomas Werge; David M. Hougaard; Jacob M. Taylor; David Skuse; Bernie Devlin; Richard Anney; Stephan J. Sanders; Somer L. Bishop; Preben Bo Mortensen; Anders D. Børglum; George Davey Smith; Mark J. Daly; Elise B. Robinson
Autism spectrum disorder (ASD) risk is influenced by common polygenic and de novo variation. We aimed to clarify the influence of polygenic risk for ASD and to identify subgroups of ASD cases, including those with strongly acting de novo variants, in which polygenic risk is relevant. Using a novel approach called the polygenic transmission disequilibrium test and data from 6,454 families with a child with ASD, we show that polygenic risk for ASD, schizophrenia, and greater educational attainment is over-transmitted to children with ASD. These findings hold independent of proband IQ. We find that polygenic variation contributes additively to risk in ASD cases who carry a strongly acting de novo variant. Lastly, we show that elements of polygenic risk are independent and differ in their relationship with phenotype. These results confirm that the genetic influences on ASD are additive and suggest that they create risk through at least partially distinct etiologic pathways.
bioRxiv | 2017
Ditte Demontis; Raymond K. Walters; Joanna Martin; Manuel Mattheisen; Thomas Damm Als; Esben Agerbo; Rich Belliveau; Jonas Bybjerg-Grauholm; Marie Bækved-Hansen; Felecia Cerrato; Claire Churchhouse; Ashley Dumont; Nicholas Eriksson; Michael J. Gandal; Jacqueline I. Goldstein; Jakob Grove; Christine Søholm Hansen; Mads Engel Hauberg; Mads V. Hollegaard; Daniel P. Howrigan; Hailiang Huang; Julian Maller; Jennifer L. Moran; Jonatan Pallesen; Duncan S. Palmer; Carsten Bøcker Pedersen; Timothy Poterba; Jesper Buchhave Poulsen; Stephan Ripke; Elise B. Robinson
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly heritable childhood behavioral disorder affecting 5% of school-age children and 2.5% of adults. Common genetic variants contribute substantially to ADHD susceptibility, but no individual variants have been robustly associated with ADHD. We report a genome-wide association meta-analysis of 20,183 ADHD cases and 35,191 controls that identifies variants surpassing genome-wide significance in 12 independent loci, revealing new and important information on the underlying biology of ADHD. Associations are enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes, as well as around brain-expressed regulatory marks. These findings, based on clinical interviews and/or medical records are supported by additional analyses of a self-reported ADHD sample and a study of quantitative measures of ADHD symptoms in the population. Meta-analyzing these data with our primary scan yielded a total of 16 genome-wide significant loci. The results support the hypothesis that clinical diagnosis of ADHD is an extreme expression of one or more continuous heritable traits.
Genome Biology | 2016
Anna K. Knight; Jeffrey M. Craig; Christiane Theda; Marie Bækvad-Hansen; Jonas Bybjerg-Grauholm; Christine Søholm Hansen; Mads V. Hollegaard; David M. Hougaard; Preben Bo Mortensen; Shantel M. Weinsheimer; Thomas Werge; Patricia A. Brennan; Joseph F. Cubells; D. Jeffrey Newport; Zachary N. Stowe; Jeanie L.Y. Cheong; Philippa Dalach; Lex W. Doyle; Yuk Jing Loke; Andrea Baccarelli; Allan C. Just; Robert O. Wright; Mara M. Téllez-Rojo; Katherine Svensson; Letizia Trevisi; Elizabeth M. Kennedy; Elisabeth B. Binder; Stella Iurato; Darina Czamara; Katri Räikkönen
BackgroundGestational age is often used as a proxy for developmental maturity by clinicians and researchers alike. DNA methylation has previously been shown to be associated with age and has been used to accurately estimate chronological age in children and adults. In the current study, we examine whether DNA methylation in cord blood can be used to estimate gestational age at birth.ResultsWe find that gestational age can be accurately estimated from DNA methylation of neonatal cord blood and blood spot samples. We calculate a DNA methylation gestational age using 148 CpG sites selected through elastic net regression in six training datasets. We evaluate predictive accuracy in nine testing datasets and find that the accuracy of the DNA methylation gestational age is consistent with that of gestational age estimates based on established methods, such as ultrasound. We also find that an increased DNA methylation gestational age relative to clinical gestational age is associated with birthweight independent of gestational age, sex, and ancestry.ConclusionsDNA methylation can be used to accurately estimate gestational age at or near birth and may provide additional information relevant to developmental stage. Further studies of this predictor are warranted to determine its utility in clinical settings and for research purposes. When clinical estimates are available this measure may increase accuracy in the testing of hypotheses related to developmental age and other early life circumstances.
Nature Genetics | 2018
Antonio F. Pardiñas; Peter Holmans; Andrew Pocklington; Valentina Escott-Price; Stephan Ripke; Noa Carrera; Sophie E. Legge; Sophie Bishop; Darren Cameron; Marian Lindsay Hamshere; Jun Han; Leon Hubbard; Amy Lynham; Kiran Kumar Mantripragada; Elliott Rees; James H. MacCabe; Steven A. McCarroll; Bernhard T. Baune; Gerome Breen; Enda M. Byrne; Udo Dannlowski; Thalia C. Eley; Caroline Hayward; Nicholas G. Martin; Andrew M. McIntosh; Robert Plomin; David J. Porteous; Naomi R. Wray; Armando Caballero; Daniel H. Geschwind
Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life and decreased life expectancy. Lack of progress in improving treatment outcomes has been attributed to limited knowledge of the underlying biology, although large-scale genomic studies have begun to provide insights. We report a new genome-wide association study of schizophrenia (11,260 cases and 24,542 controls), and through meta-analysis with existing data we identify 50 novel associated loci and 145 loci in total. Through integrating genomic fine-mapping with brain expression and chromosome conformation data, we identify candidate causal genes within 33 loci. We also show for the first time that the common variant association signal is highly enriched among genes that are under strong selective pressures. These findings provide new insights into the biology and genetic architecture of schizophrenia, highlight the importance of mutation-intolerant genes and suggest a mechanism by which common risk variants persist in the population.A new GWAS of schizophrenia (11,260 cases and 24,542 controls) and meta-analysis identifies 50 new associated loci and 145 loci in total. The common variant association signal is highly enriched in mutation-intolerant genes and in regions under strong background selection.
Molecular Psychiatry | 2018
Carsten Bøcker Pedersen; Jonas Bybjerg-Grauholm; M G Pedersen; Jakob Grove; Esben Agerbo; Marie Bækvad-Hansen; J B Poulsen; C S Hansen; John J. McGrath; T D Als; Jacqueline I. Goldstein; Benjamin M. Neale; M. J. Daly; David M. Hougaard; O. Mors; Merete Nordentoft; Anders D. Børglum; Thomas Werge; Peter B. Mortensen
The Integrative Psychiatric Research (iPSYCH) consortium has established a large Danish population-based Case–Cohort sample (iPSYCH2012) aimed at unravelling the genetic and environmental architecture of severe mental disorders. The iPSYCH2012 sample is nested within the entire Danish population born between 1981 and 2005, including 1 472 762 persons. This paper introduces the iPSYCH2012 sample and outlines key future research directions. Cases were identified as persons with schizophrenia (N=3540), autism (N=16 146), attention-deficit/hyperactivity disorder (N=18 726) and affective disorder (N=26 380), of which 1928 had bipolar affective disorder. Controls were randomly sampled individuals (N=30 000). Within the sample of 86 189 individuals, a total of 57 377 individuals had at least one major mental disorder. DNA was extracted from the neonatal dried blood spot samples obtained from the Danish Neonatal Screening Biobank and genotyped using the Illumina PsychChip. Genotyping was successful for 90% of the sample. The assessments of exome sequencing, methylation profiling, metabolome profiling, vitamin-D, inflammatory and neurotrophic factors are in progress. For each individual, the iPSYCH2012 sample also includes longitudinal information on health, prescribed medicine, social and socioeconomic information, and analogous information among relatives. To the best of our knowledge, the iPSYCH2012 sample is the largest and most comprehensive data source for the combined study of genetic and environmental aetiologies of severe mental disorders.
PLOS ONE | 2016
Jesper Buchhave Poulsen; Francesco Lescai; Jakob Grove; Marie Bækvad-Hansen; Michael Christiansen; Christian M. Hagen; Julian Maller; Christine Stevens; Shenting Li; Qibin Li; Jihua Sun; Jun Wang; Merete Nordentoft; Thomas Werge; Preben Bo Mortensen; Anders D. Børglum; Mark J. Daly; David M. Hougaard; Jonas Bybjerg-Grauholm; Mads V. Hollegaard
Stored neonatal dried blood spot (DBS) samples from neonatal screening programmes are a valuable diagnostic and research resource. Combined with information from national health registries they can be used in population-based studies of genetic diseases. DNA extracted from neonatal DBSs can be amplified to obtain micrograms of an otherwise limited resource, referred to as whole-genome amplified DNA (wgaDNA). Here we investigate the robustness of exome sequencing of wgaDNA of neonatal DBS samples. We conducted three pilot studies of seven, eight and seven subjects, respectively. For each subject we analysed a neonatal DBS sample and corresponding adult whole-blood (WB) reference sample. Different DNA sample types were prepared for each of the subjects. Pilot 1: wgaDNA of 2x3.2mm neonatal DBSs (DBS_2x3.2) and raw DNA extract of the WB reference sample (WB_ref). Pilot 2: DBS_2x3.2, WB_ref and a WB_ref replica sharing DNA extract with the WB_ref sample. Pilot 3: DBS_2x3.2, WB_ref, wgaDNA of 2x1.6 mm neonatal DBSs and wgaDNA of the WB reference sample. Following sequencing and data analysis, we compared pairwise variant calls to obtain a measure of similarity—the concordance rate. Concordance rates were slightly lower when comparing DBS vs WB sample types than for any two WB sample types of the same subject before filtering of the variant calls. The overall concordance rates were dependent on the variant type, with SNPs performing best. Post-filtering, the comparisons of DBS vs WB and WB vs WB sample types yielded similar concordance rates, with values close to 100%. WgaDNA of neonatal DBS samples performs with great accuracy and efficiency in exome sequencing. The wgaDNA performed similarly to matched high-quality reference—whole-blood DNA—based on concordance rates calculated from variant calls. No differences were observed substituting 2x3.2 with 2x1.6 mm discs, allowing for additional reduction of sample material in future projects.
Biological Psychiatry | 2017
Joanna Martin; Raymond K. Walters; Ditte Demontis; Manuel Mattheisen; S. Hong Lee; Elise B. Robinson; Isabell Brikell; Laura Ghirardi; Henrik Larsson; Paul Lichtenstein; Nicholas Eriksson; iPSYCH–Broad Adhd Workgroup; Thomas Werge; Preben Bo Mortensen; Marianne Giørtz Pedersen; Ole Mors; Merete Nordentoft; David M. Hougaard; Jonas Bybjerg-Grauholm; Naomi R. Wray; Barbara Franke; Stephen V. Faraone; Michael Conlon O'Donovan; Anita Thapar; Anders D. Børglum; Benjamin M. Neale
Background Attention-deficit/hyperactivity disorder (ADHD) shows substantial heritability and is two to seven times more common in male individuals than in female individuals. We examined two putative genetic mechanisms underlying this sex bias: sex-specific heterogeneity and higher burden of risk in female cases. Methods We analyzed genome-wide autosomal common variants from the Psychiatric Genomics Consortium and iPSYCH Project (n = 20,183 cases, n = 35,191 controls) and Swedish population register data (n = 77,905 cases, n = 1,874,637 population controls). Results Genetic correlation analyses using two methods suggested near complete sharing of common variant effects across sexes, with rg estimates close to 1. Analyses of population data, however, indicated that female individuals with ADHD may be at especially high risk for certain comorbid developmental conditions (i.e., autism spectrum disorder and congenital malformations), potentially indicating some clinical and etiological heterogeneity. Polygenic risk score analysis did not support a higher burden of ADHD common risk variants in female cases (odds ratio [confidence interval] = 1.02 [0.98–1.06], p = .28). In contrast, epidemiological sibling analyses revealed that the siblings of female individuals with ADHD are at higher familial risk for ADHD than the siblings of affected male individuals (odds ratio [confidence interval] = 1.14 [1.11–1.18], p = 1.5E-15). Conclusions Overall, this study supports a greater familial burden of risk in female individuals with ADHD and some clinical and etiological heterogeneity, based on epidemiological analyses. However, molecular genetic analyses suggest that autosomal common variants largely do not explain the sex bias in ADHD prevalence.
Translational Psychiatry | 2017
Anna Starnawska; Christine Søholm Hansen; Thomas Sparsø; Wiktor Mazin; Line Olsen; M Bertalan; A Buil; Jonas Bybjerg-Grauholm; Marie Bækvad-Hansen; David M. Hougaard; Peter B. Mortensen; Carsten Bøcker Pedersen; Mette Nyegaard; Thomas Werge; Shantel Marie Weinsheimer
Individuals with 22q11.2 deletion syndrome (DS) have an increased risk of comorbid mental disorders including schizophrenia, attention deficit hyperactivity disorder, depression, as well as intellectual disability. Although most 22q11.2 deletion carriers have the long 3-Mb form of the hemizygous deletion, there remains a large variation in the development and progression of psychiatric disorders, which suggests that alternative factors contribute to the pathogenesis. In this study we investigated whether neonatal DNA methylation signatures in individuals with the 22q11.2 deletion associate with mental disorder later in life. DNA methylation was measured genome-wide from neonatal dried blood spots in a cohort of 164 individuals with 22q11.2DS, including 48 individuals diagnosed with a psychiatric disorder. Among several CpG sites with P-value<10−6, we identified cg23546855 (P-value=2.15 × 10−7) mapping to STK32C to be associated with a later psychiatric diagnosis. Pathway analysis of the top findings resulted in the identification of several Gene Ontology pathways to be significantly enriched (P-value<0.05 after Benjamini–Hochberg correction); among them are the following: neurogenesis, neuron development, neuron projection development, astrocyte development, axonogenesis and axon guidance. In addition, we identified differentially methylated CpG sites in LRP2BP (P-value=5.37 × 10−8) to be associated with intellectual disability (F70–79), in TOP1 (P-value=1.86 × 10−7) with behavioral disorders (F90–98), in NOSIP (P-value=5.12 × 10−8) with disorders of psychological development (F80–89) and in SEMA4B (P-value=4.02 × 10−7) with schizophrenia spectrum disorders (F20–29). In conclusion, our study suggests an association of DNA methylation differences at birth with development of mental disorder later in life in 22q11.2DS individuals.
Genome Medicine | 2018
Eilis Hannon; Diana E. Schendel; Christine Ladd-Acosta; Jakob Grove; Christine Søholm Hansen; Shan V. Andrews; David M. Hougaard; Michaeline Bresnahan; Ole Mors; Mads V. Hollegaard; Marie Bækvad-Hansen; Mady Hornig; Preben Bo Mortensen; Anders D. Børglum; Thomas Werge; Marianne Giørtz Pedersen; Merete Nordentoft; Joseph D. Buxbaum; M. Daniele Fallin; Jonas Bybjerg-Grauholm; Abraham Reichenberg; Jonathan Mill
BackgroundAutism spectrum disorder (ASD) is a severe neurodevelopmental disorder characterized by deficits in social communication and restricted, repetitive behaviors, interests, or activities. The etiology of ASD involves both inherited and environmental risk factors, with epigenetic processes hypothesized as one mechanism by which both genetic and non-genetic variation influence gene regulation and pathogenesis. The aim of this study was to identify DNA methylation biomarkers of ASD detectable at birth.MethodsWe quantified neonatal methylomic variation in 1263 infants—of whom ~ 50% went on to subsequently develop ASD—using DNA isolated from archived blood spots taken shortly after birth. We used matched genotype data from the same individuals to examine the molecular consequences of ASD-associated genetic risk variants, identifying methylomic variation associated with elevated polygenic burden for ASD. In addition, we performed DNA methylation quantitative trait loci (mQTL) mapping to prioritize target genes from ASD GWAS findings.ResultsWe identified robust epigenetic signatures of gestational age and prenatal tobacco exposure, confirming the utility of DNA methylation data generated from neonatal blood spots. Although we did not identify specific loci showing robust differences in neonatal DNA methylation associated with later ASD, there was a significant association between increased polygenic burden for autism and methylomic variation at specific loci. Each unit of elevated ASD polygenic risk score was associated with a mean increase in DNA methylation of − 0.14% at two CpG sites located proximal to a robust GWAS signal for ASD on chromosome 8.ConclusionsThis study is the largest analysis of DNA methylation in ASD undertaken and the first to integrate genetic and epigenetic variation at birth. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with disease, and of using mQTL to refine the functional and regulatory variation associated with ASD risk variants.
Molecular genetics and metabolism reports | 2017
Jonas Bybjerg-Grauholm; Christian Munch Hagen; Sok Kean Khoo; Maria Louise Johannesen; Christine Søholm Hansen; Marie Bækvad-Hansen; Michael Christiansen; David M. Hougaard; Mads V. Hollegaard
Neonatal dried blood spots (DBS) are routinely collected on standard Guthrie cards for all-comprising national newborn screening programs for inborn errors of metabolism, hypothyroidism and other diseases. In Denmark, the Guthrie cards are stored at − 20 °C in the Danish Neonatal Screening Biobank and each sample is linked to elaborate social and medical registries. This provides a unique biospecimen repository to enable large population research at a perinatal level. Here, we demonstrate the feasibility to obtain gene expression data from DBS using next-generation RNA sequencing (RNA-seq). RNA-seq was performed on five males and five females. Sequencing results have an average of > 30 million reads per sample. 26,799 annotated features can be identified with 64% features detectable without fragments per kilobase of transcript per million mapped reads (FPKM) cutoff; number of detectable features dropped to 18% when FPKM ≥ 1. Sex can be discriminated using blood-based sex-specific gene set identified by the Genotype-Tissue Expression consortium. Here, we demonstrate the feasibility to acquire biologically-relevant gene expression from DBS using RNA-seq which provide a new avenue to investigate perinatal diseases in a high throughput manner.